| Date | Title | Description | Source |
| 14.11.2023 | Scotland’s Glox Therapeutics raises €4.9M to combat antimicr... | Read this article in:
Glasgow-based Glox Therapeutics, a company that aims to advance its precision... | siliconcan... |
| 23.05.2023 | m4 Award winner smartbax completes seed funding of EUR 1.2 m... | Munich-based biotech company and m4 Award winner smartbax, which develops next-generation antibiotic... | bio-m.org/... |
| 11.05.2023 | Biotech startup DiogenX secures €27.5M to develop therapeuti... | Marseille-based DiogenX, a preclinical-stage biotech company specialising in the development of panc... | siliconcan... |
| 15.09.2022 | Berlin-based Aignostics scoops €14 million to decode diagnos... | While pathologists are outstanding at interpreting individual tissue samples qualitatively, deep ana... | tech.eu/20... |
| 18.06.2021 | Nuevocor closes US$24M Series A Financing to Advance Novel G... | SINGAPORE, June 18, 2021 /PRNewswire/ -- Nuevocor, a preclinical-stage biotech company specializing ... | en.prnasia... |
| 22.07.2020 | T3 Pharma raises CHF 25M to advance bacterial cancer therapy | Founded in 2015 as a spin-off from the Biozentrum of the University of Basel, T3 Pharma built a prop... | startuptic... |
| 22.07.2020 | T3 Pharma raises CHF 25M to advance bacterial cancer therapy |
Founded in 2015 as a spin-off from the Biozentrum of the University of Basel, T3 Pharma built a pr... | startuptic... |
| 10.01.2020 | NBE-Therapeutics closes USD 22 million financing round |
NBE-Therapeutics’ best in class iADC platform creates highly potent and safe immune-stimulatory AD... | startuptic... |
| 10.01.2020 | NBE-Therapeutics closes USD 22 million financing round | NBE-Therapeutics’ best in class iADC platform creates highly potent and safe immune-stimulatory ADCs... | startuptic... |
| 26.09.2019 | Financing Round Paves the Way for T3 Pharma to Enter the Cli... |
T3 Pharmaceuticals is focusing on immuno-oncology (bacteria-based) therapies for the treatment of ... | startuptic... |
| 12.11.2018 | AMAL Therapeutics finalises CHF 33 million Series B round |
The Company will use the funds to progress its lead vaccine (ATP128) toward clinical development a... | startuptic... |
| 05.09.2017 | AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in F... | Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment F... | 3bfuturehe... |
| 03.11.2016 | NBE Therapeutics Raises CHF 20 Million in Series B Funding |
PPF Group led the round with participation from Boehringer Ingelheim Venture Fund, all other exist... | startuptic... |
| 11.04.2016 | Daily funding roundup - April 11, 2016 | Ticket Monster raised $40M; STAT-Diagnostica closed Series C; Marxent received $10M investment
Habi... | vator.tv/n... |
| 30.03.2016 | Daily funding roundup - March 30, 2016 | Zavante closed $45M Series A funding; MapD secured $10M; Invoca closed $30M Series D funding
Invoca... | vator.tv/n... |
| 30.03.2016 | Amal Therapeutics raises CHF 3 million in a Series A financi... |
Amal Therapeutics is a Swiss biotech company developing and progressing therapeutic cancer vaccine... | startuptic... |
| 14.10.2014 | Rigontec Raises €9.45M in Series A Financing | Rigontec GmbH, a Bonn, Germany-based biopharmaceutical company developing RNA-based immunotherapeuti... | finsmes.co... |
| 25.03.2014 | Amal Therapeutics, un exemple de recherche de Seed financing... |
La co-fondatrice et CEO d'Amal Therapeutics était présente la semaine dernière au BioMed Up au Cam... | startuptic... |
| 24.03.2014 | Emerging sources of early-stage life science funding embrace... | “The biggest challenge for the pharmaceutical company is actually coming up with a product that work... | medcitynew... |
| 21.02.2014 | Amal Therapeutics Raises Seed Funding | Amal Therapeutics SA, a Geneva, Switzerland and Berlin, Germany-based company focusing on the develo... | finsmes.co... |
| 20.02.2014 | Amal Therapeutics SA raises seed round from Boehringer Ingel... |
Amal Therapeutics was founded in 2012 as a spin-off of the University of Geneva. The company is de... | startuptic... |
| 29.05.2013 | GSK acquires Okairos AG for EUR 250 mio |
Swiss-based Okairos, a private company, has developed a novel vaccine platform technology which is... | startuptic... |
| 06.05.2013 | STAT-Diagnóstica cierra una ronda de €17M e incorpora invers... | 06/05/2013
Nota de Prensa
STAT-DIAGNOSTICA CIERRA UNA RONDA DE €17 MILLONES E INCORPORA INVERSORES... | webcapital... |
| 06.05.2013 | STAT-Diagnostica Closes €17M Series B Financing | STAT-Diagnostica, a Barcelona, Spain-based provider of a Near Patient Testing diagnostic system, clo... | finsmes.co... |
| 11.04.2013 | Eyevensys Raises Funds from Boehringer Ingelheim Venture Fun... | Eyevensys, a Paris, France-developer of a new non-viral gene therapy process to treat ocular illness... | finsmes.co... |
| 03.12.2012 | ArmaGen Technologies Raises $17M in Series A Funding | ArmaGen Technologies, a Santa Monica, CA-based developer of brain-penetrating recombinant protein th... | finsmes.co... |
| 31.03.2010 | Ben Venue, Roxane parent launches $135M life sciences fund | These are new areas of investment for Boehringer Ingelheim, which in Ohio is known for making generi... | medcitynew... |
| - | Emerging sources of early-stage life science funding embrace... | It was nice to hear one healthcare executive and investor after another respond to the question, “wh... | medcitynew... |
| - | AMAL Therapeutics finalises €29 million (CHF 33.2 million) S... | November 12, 2018
AMAL Therapeutics SA (AMAL), a Swiss biotech developing peptide-based therapeut... | htgf.de/en... |
| - | Aignostics raises €5m Seed Round to advance AI-powered patho... | August 28, 2020
Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Ins... | htgf.de/en... |
| - | Abalos Therapeutics Launches with €12M Series A Round to Dev... | October 15, 2019
Abalos Therapeutics announced today a EUR 12 million Series A financing round esta... | htgf.de/en... |
| - | Bayer and Boehringer Ingelheim invest in HTGF III | May 29, 2018
Bayer and Boehringer Ingelheim’s investment fund BIVF (Boehringer Ingelheim Venture Fu... | htgf.de/en... |
| - | Tacalyx Raises €7 Million in Seed Funding to Generate First ... | September 25, 2019
Tacalyx, a biotech company focused on the discovery and development of novel ant... | htgf.de/en... |
| - | Amal Therapeutics raises CHF 3 million in a Series A financi... | March 30, 2016
Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financi... | htgf.de/en... |
| - | Abalos Therapeutics Completes Series A Extension Bringing To... | October 14, 2021
Additional EUR 32.5 million will support clinical readiness and accelerate lead im... | htgf.de/en... |
| - | Ben Venue, Roxane parent launches $135M life sciences fund | The German parent of Ben Venue and Roxane drug-making facilities in Ohio has launched a $135 million... | medcitynew... |
